UK Markets open in 5 hrs 1 min

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3700-0.0300 (-1.25%)
At close: 4:00PM EST

2.3700 0.00 (0.00%)
After hours: 7:47PM EST

Trevena, Inc.

955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
http://www.trevena.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees24

Key executives

NameTitlePayExercisedYear born
Ms. Carrie L. BourdowPres, CEO & Director901.08kN/A1963
Dr. Mark A. DemitrackSr. VP & Chief Medical Officer638.99kN/A1958
Mr. Robert T. YoderSr. VP & Chief Bus. Officer490.64kN/A1966
Dr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardN/AN/AN/A
Mr. Barry ShinSr. VP & CFON/AN/A1972
Mr. Scott ApplebaumChief Legal and Compliance Officer & Sr. VP of Regulatory AffairsN/AN/A1967
Mr. Michael CatalanoVP of MarketingN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Corporate governance

Trevena, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.